A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.
about
Vaccines for preventing herpes zoster in older adultsVaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adultsUnderstanding natural herpes simplex virus immunity to inform next-generation vaccine designVaricella zoster vaccines and their implications for development of HSV vaccinesMultidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox.Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled studyHerpes zoster surveillance using electronic databases in the Valencian Community (Spain).A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.A site of varicella-zoster virus vulnerability identified by structural studies of neutralizing antibodies bound to the glycoprotein complex gHgL.Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.Effector and Central Memory Poly-Functional CD4(+) and CD8(+) T Cells are Boosted upon ZOSTAVAX(®) VaccinationRecommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)Efficacy of varicella (VZV) vaccination: an update for the clinician.Genome-wide analysis of T cell responses during acute and latent simian varicella virus infections in rhesus macaquesPathogenesis and current approaches to control of varicella-zoster virus infections.Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults.Correlate of immune protection against HSV-1 genital disease in vaccinated women.From discovery to licensure, the Adjuvant System story.Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly.The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus.The herpes zoster subunit vaccine.Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections.Herpes zoster and the search for an effective vaccine.Incidence and consequences of varicella in children treated for cancer in Guatemala.Aging of the immune system: Focus on inflammation and vaccination.Vaccine profile of herpes zoster (HZ/su) subunit vaccine.A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.Non-clinical safety assessment of single and repeated administration of gE/AS01 zoster vaccine in rabbits.Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine.Adjuvant system AS01: helping to overcome the challenges of modern vaccines.Evaluation of peptide selection approaches for epitope-based vaccine design.Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine.Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine.Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging.
P2860
Q24186050-B24B1F85-3D73-4310-BC62-0F18E4EF1B72Q24193819-3867C096-E332-48CF-963D-9DD78FC7285DQ26741484-4208CF35-237F-471F-BF52-5DE01BDC043EQ28280820-FFEA87A1-EE12-424E-A58B-36C43503382FQ33683179-D16603E5-DDD1-4596-BDF7-66DD438B6AD1Q33724403-6766C1D4-A2A1-4300-ABE4-518655F539CAQ34446365-E0994A86-7C7F-4364-B463-548961520072Q35008196-E2899AB8-033B-4D57-AB62-7656932A4DD1Q35081168-AA3EEE13-5868-444B-B2B8-D7B5BAC40DABQ35616152-C6A97E8E-A1CA-4BE9-B1D0-6FE1DCA16F67Q36024466-72E1DFBD-6D8C-48D6-979A-492F0BD5C8DDQ36237622-1990D19A-BB96-4526-B9C5-23046D79B468Q37135485-EE8CBCB3-6083-493B-9297-43B3ECED4775Q37158220-36B59F27-0E2F-484D-97AD-4CE403AC1DE8Q37252780-BD8ED4ED-23C8-4621-99EB-B651E6DEEB25Q37263293-121FE27C-336C-4404-A9C9-144A1B73F4E8Q37472498-8BB203F3-3915-412E-8C16-5700092470C8Q37604473-EAA4F102-3402-4B70-BA35-D3393E9C7469Q37619140-8922CD32-038E-4012-BECC-FCEAB17AFC23Q37643309-1A972F44-A500-4B6C-8505-855547B78CDCQ37713779-34A0CC13-062B-4233-8CC0-BB3BF73FA08BQ38682515-5202E059-BB37-4412-87D3-E055DE15E1A3Q38728931-C1DF157F-811C-491E-886D-D04CE7729B73Q38731791-F86E3021-0B94-43B7-B992-D9EAE5E270FBQ38831062-F8401B0D-1E9F-44E9-947F-71162B845E63Q38847684-5AB4F8CA-0DFF-4033-963F-F12BE7FA1CB0Q38946555-2EBDFAA7-86F7-4B6D-ACF6-7DEED401C6C1Q40208840-59805475-4F21-4D71-82C4-CB28B8B64BFBQ40234780-CEE2A737-33D5-4EE2-97C0-1635B917FCDFQ40757793-BDAEB5E9-9255-430C-B593-9F7E2DD6347FQ40895773-7AE42CB9-C13E-4ACC-A38C-1FF251D4C95BQ41264182-F49E6A1A-667B-4DA8-A318-A673C470029BQ42051427-98D54FFE-7207-484F-93D0-E89696E286E3Q42241375-9E7B8230-9EF5-43CE-B8F4-7100F92F7481Q42273664-F98E6FEA-F3B1-4F1B-B9D7-714E392D6C61Q42279944-60CDE3AB-6F24-4F12-B268-7706F2BE2791Q44168441-4A610C20-6CE3-45FA-A75C-1C0B8A9CF45BQ46046365-26BC31FA-F8CD-4A1F-B849-E3418298DE88Q46892547-A8E38A30-BF39-4F3D-BF95-C839C9B61E76Q47140159-E2E9B18B-ADA9-4436-AFD1-664915211345
P2860
A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
A phase 1/2 clinical trial eva ...... ate in young and older adults.
@en
A phase 1/2 clinical trial eva ...... ate in young and older adults.
@nl
type
label
A phase 1/2 clinical trial eva ...... ate in young and older adults.
@en
A phase 1/2 clinical trial eva ...... ate in young and older adults.
@nl
prefLabel
A phase 1/2 clinical trial eva ...... ate in young and older adults.
@en
A phase 1/2 clinical trial eva ...... ate in young and older adults.
@nl
P2093
P2860
P356
P1476
A phase 1/2 clinical trial eva ...... ate in young and older adults.
@en
P2093
Edouard Ledent
Frédéric Clement
Geert Leroux-Roels
Isabel Leroux-Roels
Pierre Vandepapelière
Thomas C Heineman
Ventzislav Vassilev
P2860
P304
P356
10.1093/INFDIS/JIS497
P407
P577
2012-08-07T00:00:00Z